Company news
Ironwood Pharmaceuticals, Inc. news in 2021
Ironwood Pharmaceuticals, Inc.'s news releases, calls and decks from 2021, newest first.
Ironwood Pharmaceuticals Appoints Sravan K. Emany as Chief Financial Officer
November 30, 2021
Ironwood Pharmaceuticals Reports Third Quarter 2021 Results and Provides Corporate Development Update
November 3, 2021
Ironwood Pharmaceuticals Expands Pipeline by Signing an Option Agreement to Acquire an Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Biliary Cholangitis (PBC) in the U.S.
November 3, 2021
More than 90% of Surveyed IBS-C Patients Who Had an ER Visit or Hospitalization in the Past Year Identified Abdominal Pain as a Symptom That Led to the Visit, According to Data Announced by Ironwood Pharmaceuticals at ACG 2021
October 24, 2021
Ironwood Pharmaceuticals to Host Third Quarter 2021 Investor Update Call
October 20, 2021
Ironwood Pharmaceuticals to Participate in Upcoming September Investor Conferences
September 1, 2021
Ironwood Pharmaceuticals Announces FDA Approval of Revised LINZESS® (linaclotide) Label
August 25, 2021
Ironwood Pharmaceuticals Reports Strong Second-Quarter 2021 Results, Raises Full-Year Guidance
August 4, 2021
Ironwood Pharmaceuticals Appoints John Minardo as Chief Legal Officer
August 2, 2021
Ironwood Pharmaceuticals to Host Second Quarter 2021 Investor Update Call
July 21, 2021
Ironwood Pharmaceuticals Announces That The American Journal of Gastroenterology Publishes Full Results from Positive LINZESS® (linaclotide) Phase IIIb Trial in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)
June 15, 2021
Ironwood Pharmaceuticals Announces Leadership Updates
June 6, 2021
Ironwood Pharmaceuticals Announces Agreement with Teva Involving LINZESS® (linaclotide) 72 mcg Dosage Strength
May 25, 2021
More Than a Third of Surveyed IBS-C Patients Reported That Their Symptoms Worsened During COVID-19 According to New Survey Findings Presented by Ironwood Pharmaceuticals at Digestive Disease Week® (DDW)
May 23, 2021
Ironwood Pharmaceuticals to Present New Linaclotide Data and Unveil Findings From GI Disease Surveys at Digestive Disease Week® 2021
May 16, 2021
Ironwood Pharmaceuticals Reports First Quarter 2021 Results
May 5, 2021
Ironwood Pharmaceuticals Announces New $150 Million Share Repurchase Program
May 5, 2021
Ironwood Pharmaceuticals to Host First Quarter 2021 Investor Update Call
April 21, 2021
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results, Exceeding or Meeting Full Year 2020 Financial Guidance; Provides Full Year 2021 Financial Guidance
February 16, 2021
Ironwood Pharmaceuticals Announces CEO Transition
February 7, 2021
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2020 Investor Update Call
February 2, 2021
Ironwood Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 4, 2021
Calls in 2021
- Ironwood Pharmaceuticals (NASDAQ:IRWD) Q3 2021 Earnings Call
Nov 4, 2021
Transcript - Ironwood Pharmaceuticals (NASDAQ:IRWD) Q2 2021 Earnings Call
Aug 5, 2021
Transcript - Ironwood Pharmaceuticals (NASDAQ:IRWD) Q1 2021 Earnings Call
May 6, 2021
Transcript - Ironwood Pharmaceuticals (NASDAQ:IRWD) Q4 2020 Earnings Call
Feb 17, 2021
Transcript
Decks in 2021
- Q3 2021 Earnings Presentation
Earnings · 21 slides · Nov 4, 2021
- Q2 2021 Earnings Presentation
Earnings · 16 slides · Aug 5, 2021
- Q1 2021 Earnings Presentation
Earnings · 17 slides · May 6, 2021
- SVB Leerink Global Healthcare Conference 2021
Conference · 24 slides · Feb 26, 2021
- FY2020 Earnings Presentation
Earnings · 25 slides · Feb 17, 2021
- J.P. Morgan Healthcare Conference 2021
Conference · 42 slides · Jan 11, 2021